Benchling’s "State of Tech in Biopharma" report is here 🧪 🧬 🔬 It’s a must-read for anyone tracking the intersection of technology and life sciences. AI models like AlphaFold and EvolutionaryScale’s ESM3 are transforming science. But the right tech infrastructure is just as critical. Without the tools to connect wet and dry labs, standardize data, and scale workflows, even the best AI models fall short. The report highlights that only 14% of large biopharma companies — and just 3% of small ones — are prepared for AI at scale. At Lux, we’re proud to support companies like Benchling and EvolutionaryScale as they drive the convergence of biotech and AI, laying the foundation for faster, smarter drug discovery. Read the report to explore how AI is reshaping the future:https://lnkd.in/eAdXV9Ck
#AI adoption is rising in #biopharma, but there’s a clear divide: large companies are adopting AI/ML at nearly 3x the rate of small companies. We asked hundreds of industry leaders why — here’s what we learned. 💡 AI is the second-highest investment priority for large biopharma, while small biopharma places it next to last. 💡 Small biopharma are prioritizing foundational tech instead, adopting R&D platforms (89%) over AI/ML (23%) or robotics and automation (27%). 💡 Even so, only 25% of large companies and 9% of small companies report AI readiness at the foundational level. Discover why large and small companies are making big bets — on different tech strategies: https://lnkd.in/eAdXV9Ck